` PAA (Pharmaust Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

PAA
vs
S
S&P/ASX 300

Over the past 12 months, PAA has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
PAA vs S&P/ASX 300

Loading
PAA
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PAA vs S&P/ASX 300

Loading
PAA
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
PAA vs S&P/ASX 300

Loading
PAA
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Pharmaust Ltd vs Peers

S&P/ASX 300
PAA
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Pharmaust Ltd
Glance View

Market Cap
81.2m AUD
Industry
Pharmaceuticals

PharmAust Ltd. is a pharmaceutical company, which provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2001-10-05. The firm is focused on developing therapeutics for cancer, neurodegenerative diseases and viral infections in humans and cancer for pet dogs. The firm's lead candidate, monepantel (MPL), is a small molecule drug primarily being developed as a safe and potent treatment for cancer. The MPL can also be used for neurodegenerative diseases such as Motor Neuron Disease, Parkinson's Disease, and Alzheimer's Disease. The company has completed Phase I clinical trials with MPL in humans and dogs diagnosed with solid tumors. The firm has also initiated a preclinical program to screen its portfolio of aminoacetonitrile (AAD) compounds for anticancer activity.

PAA Intrinsic Value
0.013 AUD
Overvaluation 92%
Intrinsic Value
Price
Back to Top